SIGA Technologies, Inc.  

(Public, NASDAQ:SIGA)   Watch this stock  
Find more results for Rose Haynes�
+0.01 (0.71%)
Real-time:   12:05PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.38 - 1.41
52 week 1.22 - 4.15
Open 1.41
Vol / Avg. 169,590.00/405,754.00
Mkt cap 75.44M
P/E     -
Div/yield     -
EPS -0.29
Shares 53.50M
Beta 2.13
Inst. own 28%
Nov 4, 2014
Q3 2014 SIGA Technologies Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 4, 2014
Q2 2014 SIGA Technologies Inc Earnings Call
Jul 31, 2014
Q2 2014 SIGA Technologies Inc Earnings Release
Jun 2, 2014
SIGA Technologies at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -453.15% -311.22%
Operating margin -729.55% -426.07%
EBITD margin - -408.39%
Return on average assets -5.57% -11.46%
Return on average equity -92.73% -75.97%
Employees 34 -
CDP Score - -


Suite 1700, 660 Madison Avenue
NEW YORK, NY 10065
United States - Map
+1-212-6729100 (Phone)
+1-212-6973130 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


SIGA Technologies, Inc. (SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. The Company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. The Company�s product include ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The Company�s lead product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. On May 13, 2011, it signed the BARDA Contract pursuant to which it agreed to deliver two million courses of ST-246 to the Strategic Stockpile.

Officers and directors

Eric A. Rose M.D. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Daniel J. Luckshire Chief Financial Officer, Executive Vice President, Secretary
Age: 43
Bio & Compensation  - Reuters
William J. Haynes Executive Vice President, General Counsel
Age: 56
Bio & Compensation  - Reuters
Dennis E. Hruby Ph.D. Chief Scientific Officer, Vice President
Age: 62
Bio & Compensation  - Reuters
James J. Antal CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Michael J. Bayer Independent Director
Age: 66
Bio & Compensation  - Reuters
Thomas E. Constance Independent Director
Age: 77
Bio & Compensation  - Reuters
Jeffrey B. Kindler Independent Director
Age: 58
Bio & Compensation  - Reuters
Joseph W. Marshall III Independent Director
Age: 61
Bio & Compensation  - Reuters